CPA, Managing Partner - Emerging Markets
View full biography
Emerging Markets
CohnReznick’s Emerging Markets practice focuses on fast-growing, entrepreneurial, middle-market companies operating in industries that are disrupting traditional business thinking and providing innovative solutions to everyday challenges. We combine our industry focus with an understanding of business, operational, accounting, and tax issues facing rapidly expanding companies to support their growth and bring real-time solutions to our clients. Whether its audit and tax compliance, developing strategies for domestic and international expansion, planning for a liquidity event, or improving internal processes, our professionals have the industry knowledge and technical skills to identify opportunities and resolve complex issues. Our experience serving privately held, venture capital, and private equity-backed and publicly traded companies at each stage of their life cycle allows us to provide resources and integrated solutions to address a wide range of issues and challenges.
Technology and media companies are vital components of the U.S. economy. These visionary businesses provide innovative products and services, create new jobs, strive to make a frictionless environment, and are growing aggressively. Their vision for growth often requires significant infusions of capital, the ability to attract, retain, and incentivize talent. They must also develop processes and internal controls to address the concerns of investors and regulators. Customer acquisition and servicing, while charting expenses and identifying new areas for growth, create significant challenges for management teams. Industry segments we serve include:
- Software, Software as a Service, and technology-enabled services
- Fintech
- Digital media
- Cybersecurity
- Gaming and entertainment
- Internet-related services and social media
Life sciences organizations face myriad financial, operational, regulatory, and capital-raising challenges. Managing growth, raising capital, or planning for a future product launch requires advisors who understand your industry and how you do business, and also have the resources to proactively address these business needs and goals. CohnReznick provides a range of services that help improve financial reporting and operational efficiency and minimize tax obligations. Industry segments we serve include:
- Biotechnology
- Diagnostics and therapeutics
- Medical devices
- Contract research organizations
- Healthcare IT
Today’s renewable energy industry faces a variety of regulatory, capital, and compliance challenges. Sustainability has become an integral component of corporate business plans. CohnReznick’s Renewable Energy practice boasts a national team of highly experienced professionals with extensive industry credentials. Our knowledge of the rapidly changing and nuanced industry landscape, along with our ability to address capital market needs, allows us to proactively address our clients’ issues and needs. We provide services to financial institutions, infrastructure funds, strategic participants (independent power producers and utilities), and leading global clean-energy developers. Industry segments we serve include:
- Wind and solar
- Storage
- Cleantech
- Utilities
This nascent industry faces significant regulatory challenges and is poised to continue to expand and establish itself as a major domestic and global industry. Cannabis companies need advisors who can apply industry knowledge with technical skills to help businesses comply with changing regulations, demonstrate transparency to investors, develop the business and technology infrastructure to support rapid growth, and prepare for a future liquidity event if desired. We provide services to multistate operators, investors, public and private companies, real estate investment trusts, and private equity funds. Industry segments we serve include:
- Medical
- Adult use
- Hemp
- Cannabidiol
Related Services
This has been prepared for information purposes and general guidance only and does not constitute legal or professional advice. You should not act upon the information contained in this publication without obtaining specific professional advice. No representation or warranty (express or implied) is made as to the accuracy or completeness of the information contained in this publication, and CohnReznick LLP, its members, employees and agents accept no liability, and disclaim all responsibility, for the consequences of you or anyone else acting, or refraining to act, in reliance on the information contained in this publication or for any decision based on it.
Related Insights
-
InsightEnabling diversity and inclusion in clean energy adoptionLike many other industrial sectors, the U.S. solar and wind industries have a mixed record of promoting gender and racial diversity across their workforces. While deliberate efforts to evolve and progress have been undertaken in recent years, much work remains to be done to make these industries more inclusive.
-
InsightTECHNOLOGY: Things to consider when hiring your first work-from-anywhere employeeCohnReznick professionals talked to TechCrunch about taxes, compensation, and other factors to keep in mind when hiring employees who will be fully remote.
-
InsightPerspective: New IRS ‘Marijuana Industry’ page offers useful resources, but few new insightsMichael HarlowWhile it is good to see the IRS acknowledging the marijuana industry and aggregating useful links, the page overall offers little new information. Read more.
-
InsightNavigating government funding compliance for life sciences companies: Optimize your indirect rateKristen Soles, Robert GutierrezIn order to maximize cost recovery and profitability, government grantees should develop indirect rates based on their organizational structure. Learn more.
-
InsightLIFE SCIENCES: The role of technology, data, and analytics for companies adjusting to coronavirus-driven changePaul RicciLife sciences companies face extraordinary challenges in returning to full operations once the COVID-19 pandemic subsides. New requirements for remote work, social distancing, and reduced lab capacity have severely disrupted development and production of new products, as well as enrollment and ongoing participation in clinical trials. At the same time, businesses are actively involved in clinical trials of potentially life-saving therapeutics, vaccines, and medical devices.